The diabetes drug Ozempic has demonstrated remarkable anti-aging effects in the first clinical trial to directly measure its impact on biological aging, with participants becoming an average of 3.1 years biologically younger after 32 weeks of treatment. The findings provide the strongest evidence yet that GLP-1 drugs like semaglutide may offer benefits far beyond their established roles in diabetes management and weight loss. First Direct Clinical Evidence of Anti-Aging Effects Varun Dwaraka fro...